Elsevier

Journal of Infection

Volume 6, Issue 3, May 1983, Pages 247-255
Journal of Infection

Original article
Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate

https://doi.org/10.1016/S0163-4453(83)93645-9Get rights and content

Summary

The antibody response in mice to Neisseria meningitidis (meningococcal) group C polysaccharide could be modified by its conjugation to proteins, i.e. tetanus toxoid. Whereas the pure polysaccharide behaved as a T-independent antigen, the polysaccharide-protein conjugate was clearly a T-dependent antigen, as shown by the pronounced IgG response after the first dose and by the booster effect after the second dose. In comparison, group C polysaccharide—outer membrane protein complexes isolated from the cell-free culture liquid of a meningococcal culture induced only a low level of IgG antibodies.

Conjugation did not result in a reversion of tetanus toxoid to toxin. Tetanus toxoid present in the conjugate was as immunogenic as tetanus vaccine.

References (24)

  • BeuveryEC

    Immunisation against bacterial meningitis

    J Infect

    (1981)
  • HaverkampJ et al.

    Characterization of Neisseria meningitidis capsular polysaccharides by pyrolysis mass spectrometry

    Anal Biochem

    (1980)
  • GotschlichEC et al.

    Prospects for the prevention of bacterial meningitis with polysaccharide vaccines

    Bull WHO

    (1978)
  • GoldschneiderI et al.

    Human immunity to the meningococcus. I. The role of humoral antibodies

    J Exp Med

    (1969)
  • GoldschneiderI et al.

    Human immunity to the meningococcus. II. Development of natural immunity

    J Exp Med

    (1969)
  • RobertsRB

    The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man

    J Exp Med

    (1970)
  • WellerPF et al.

    The role of encapsulation and host age in the clearance of Haemophilus influenzae bacteremia

    J Infect Dis

    (1977)
  • PeltolaH et al.

    Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 month to 5 years of age in Finland

    Pediatrics

    (1977)
  • BakerPJ et al.

    Quantitative and qualitative studies on the primary antibody response to pneumococcal polysaccharide at the cellular level

    J Immunol

    (1969)
  • BakerPJ et al.

    Characterization of the antibody response to type III pneumococcal polysaccharide at the cellular level. I. Dose-response studies and the effect of prior immunization on the magnitude of the antibody response

    Immunology

    (1971)
  • DavieJM et al.

    Role of T-lymphocytes in the humoral immune response. I. Proliferation of B lymphocytes in thymus-deprived mice

    J Immunol

    (1974)
  • Braley-MullenH

    Secondary IgG response to type III pneumococcal polysaccharide. III. T-cell requirement for development of B memory cells

    Eur J Immunol

    (1977)
  • Cited by (9)

    • Replacing antibodies with modified DNA aptamers in vaccine potency assays

      2017, Vaccine
      Citation Excerpt :

      To explore the feasibility of using aptamers in a vaccine potency assay, we chose a polysaccharide vaccine conjugated to the protein carrier CRM197. CRM197 is a non-toxic form of diphtheria toxin used in many vaccines to improve the immunogenicity of a conjugated antigen such as a polysaccharide [14,15]. CRM197 is currently used in approved conjugate vaccines against meningitis, pneumococcus and Haemophilus influenza B [16,17] to improve immunogenicity.

    • Overview of the development and current use of CRM<inf>197</inf> conjugate vaccines for pediatric use

      2010, Vaccine
      Citation Excerpt :

      Glycoconjugate vaccines are made by coupling the polysaccharide capsule portion of the organism to a carrier protein. This combination is more immunogenic than the saccharide alone and is also capable of inducing T-cell memory booster responses upon revaccination [2]. Conjugate vaccines have been developed using several protein carriers, one of which is CRM197.

    • The impact of protein-conjugate polysaccharide vaccines: An endgame for meningitis?

      2013, Philosophical Transactions of the Royal Society B: Biological Sciences
    View all citing articles on Scopus
    *

    Present address: Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis, P.O. Box 9190, 1006 AD Amsterdam, The Netherlands.

    View full text